UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, DC 20549
______________________
FORM 8-K
CURRENT REPORT
PURSUANT TO SECTION 13 OR 15(d)
OF THE SECURITIES EXCHANGE ACT OF 1934
Date of report (Date of earliest event reported): September 20, 2005
PAR PHARMACEUTICAL COMPANIES, INC.
(Exact name of registrant as specified in its charter)
Delaware (State or other jurisdiction of | File Number 1-10827 | 22-3122182 |
300 Tice Boulevard, Woodcliff Lake, New Jersey (Address of principal executive offices) | 07677 (Zip Code) |
Registrant’s telephone number, including area code: (201) 802-4000
Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (seeGeneral Instruction A.2. below):
o
Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
o
Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
o
Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
o
Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))
Item 8.01.Other Events.
Par Pharmaceutical Companies, Inc. recently announced an organizational restructuring that included the creation of two new positions to facilitate the management of its branded and generic pharmaceutical businesses. Michael Graves, formerly Senior Vice President, Corporate Development and Strategic Planning, has been promoted to the newly-created position of President, Generic Products Division. John A. MacPhee, formerly Senior Vice President, Branded Marketing and Sales, has been promoted to the newly-created position of President, Branded Products Division.
A copy of the Press Release announcing the foregoing has been attached hereto asExhibit 99.1.
Item 9.01.Financial Statements and Exhibits.
(c)
Exhibits.
99.1.
Press Release, dated as of September 20, 2005, by Par Pharmaceutical Companies, Inc.
SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned thereunto duly authorized.
Dated as of: September 22, 2005
PAR PHARMACEUTICAL COMPANIES, INC.
(Registrant)
/s/ Dennis J. O’Connor
Name Dennis J. O’Connor
Title: Vice President and Chief Financial Officer
EXHIBIT INDEX
EXHIBIT
DESCRIPTION
99.1
Press Release, dated as of September 20, 2005, by Par Pharmaceutical Companies, Inc.